An Open-Label Extension of BPS-MR-PAH-201 in Pulmonary Arterial Hypertension (PAH) Patients.
This study is an open-label study for patients who participated in the BPS-MR-PAH-201 study and have volunteered to continue treatment for PAH with BPS-MR tablets. Each patient will return to the clinic following enrollment in the study at 3, 6, and 12 months, and annually thereafter for assessment.
Patients who remained on study drug and completed all assessments during the Treatment Phase of Study BPS-MR-PAH-201 are eligible for this study.
Female patients must either be physiologically incapable of childbearing or be practicing an
acceptable method of birth control (e.g. approved hormonal contraceptive, barrier method, such
as condom or diaphragm, used with a spermicide, or an intrauterine device).